Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 1/2019

01-02-2019 | Human Immunodeficiency Virus | Behavioral Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Interventions to Reduce Drug Use Among Methamphetamine Users at Risk for HIV

Authors: Karen F. Corsi, Steve Shoptaw, Musheng Alishahi, Robert E. Booth

Published in: Current HIV/AIDS Reports | Issue 1/2019

Login to get access

Abstract

Purpose of Review

This paper reports on the results of a study comparing two behavioral treatments for methamphetamine users. The outcome was the effectiveness of the interventions in reducing meth use. The interventions were contingency management (CM) and contingency management plus strengths-based case management (CM/SBCM).

Recent Findings

CM/SBCM was found to be associated with attending more sessions for people who reported being in a couple. Also, participants who earned more money in the first part of the study were more likely to have more clean urinalysis in the second part of the study. Latent class analysis identified a class of participants who were in a couple, without sexual abuse history, and less meth use at baseline. This class tended to have more clean urinalysis in the CM/SBCM intervention.

Summary

These results indicate that incentive-based interventions with case management may be useful for helping meth users reduce their drug use.
Literature
1.
Substance Abuse and mental health Service Administration (SAMHSA). Results from the 2016 National Survey on Drug Use and Health: National findings. Rockville, MD: Office of Applied Studies, 2017. (HHS Publication No. SMA 17–5044, NSDUH Series H-52).
2.
National Institute on Drug Abuse (NIDA). Research Report Series: Methamphetamine. National Institutes of Health, September 2013.
3.
National Institute on Drug Abuse (NIDA). Epidemiologic trends in drug abuse: proceedings of the Community Epidemiologic Work Group, Highlights and Executive Summary. Bethesda, Maryland: U.S. Department of Health and Human Services: National Institutes of Health: Division of Epidemiology, Services, and Prevention Research, 2014.
4.
U.S. Drug Enforcement Administration (DEA). National drug threat assessment 2008: methamphetamine. U.S. Drug Enforcement Administration, 2008.
5.
Hoxworth T. Patterns and trends in drug abuse in Denver and Colorado: January–December 2005. Community Epidemiology Work Group (CEWG), 2006.
6.
7.
8.
•• Kral AH, Lorvick J, Martinez A, Lewis MA, Orr WA, Anderson R, et al. HIV prevalence and risk among heterosexual methamphetamine injectors in California. Subst Use Misuse. 2011;46(9):1081–9. https://​doi.​org/​10.​3109/​10826084.​2011.​557136. This study describes high risk behaviors among heterosexual methamphetamine users and thereby highlights the need for effective interventions to reduce meth use among this population. CrossRefPubMed
9.
Mansergh G, Purcell DW, Stall R, et al. CDC consultation on methamphetamine use and sexual risk behavior for HIV/STD infection: summary and suggestions. Public Health Rep. 2006;121:127–32.CrossRefPubMedPubMedCentral
10.
Krawczyk CS, Molitor F, Ruiz J, et al. Methamphetamine use and HIV risk behaviors among heterosexual men - preliminary results from five Northern California counties, December 2001–November 2003. Morb Mortal Wkly Rep. 2006;55(10):273–7.
11.
Centers for Disease Control and Prevention. Methamphetamine use and HIV risk behaviors among heterosexual men--preliminary results from five northern California counties, December 2001–November 2003. MMWR Morb Mortal Wkly Rep. 2006;55(10):273–7.
12.
Koblin BA, Husnik MJ, Colfax G, Huang Y, Madison M, Mayer K, et al. Risk factors for HIV infection among men who have sex with men. AIDS. 2006;20:731–9.CrossRefPubMed
13.
Ostrow DG, Plankey MW, Cox C, Li X, Shoptaw S, Jacobson LP, et al. Specific sex drug combinations contribute to the majority of recent HIV seroconversions among MSM in the MACS. J Acquir Immune Defic Syndr. 2009;51(3):349–55.CrossRefPubMedPubMedCentral
14.
Plankey MW, Ostrow DG, Stall R, Cox C, Li X, Peck JA, et al. The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2007;45(1):85–92.CrossRefPubMedPubMedCentral
15.
Shoptaw S, Reback CJ, Freese TE. Patient characteristics, HIV serostatus, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles. J Addict Dis. 2002;21(1):91–105.CrossRefPubMed
16.
Shoptaw S, Reback CJ, Peck JA, et al. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend. 2005;78(2):125–34.CrossRefPubMed
17.
Colfax G, Coates TJ, Husnik MJ, et al. Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men. J Urban Health. 2005;82(1):I62–70.CrossRefPubMedPubMedCentral
18.
Reback CJ. HIV risk behaviors of gay and bisexual male methamphetamine users contacted through street outreach. J Drug Issues. 1999;29:155–66.CrossRef
19.
Dew BJ, Elifson KW, Sterk CE. Differences in HIV sexual risk behaviors between heterosexual and non-heterosexual male users of methamphetamine. J Drug Issues. 2007;37:281–98.CrossRef
20.
Baskin-Sommers A, Sommers I. The co-occurrence of substance use and high-risk behaviors. J Adolesc Health. 2006a;38:609–11.CrossRefPubMed
21.
Lorvick J, Martinez A, Gee L, Kral AH. Sexual and injection risk among women who inject methamphetamine in San Francisco. J Urban Health. 2006;83(3):497–505.CrossRefPubMedPubMedCentral
22.
Zule WA, Costenbader EC, Meyer WJ, Wechsberg WM. Methamphetamine use and risky sexual behaviors during heterosexual encounters. Sex Transm Dis. 2007;34(9):689–94.CrossRefPubMed
23.
Semple SJ, Patterson TL, Grant I. Female methamphetamine users: social characteristics and sexual risk behavior. Women Health. 2004a;40(3):35–50.CrossRefPubMed
24.
Farabee D, Prendergast M, Cartier MA. Methamphetamine use and HIV risk among substance-abusing offenders in California. J Psychoactive Drugs. 2002;34(3):295–300.CrossRefPubMed
25.
Wohl AR, et al. HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexual. J Acquir Immune Defic Syndr. 2002;31:354–60.CrossRefPubMed
26.
Gibson DR, Leamon MH, Flynn N. Epidemiology and public health consequences of methamphetamine use in California’s Central Valley. J Psychoactive Drugs. 2002;34(3):313–9.CrossRefPubMed
27.
Molitor F, Truax SR, Ruiz JD, Sun RK. Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West J Med. 1998;168(2):93–7.PubMedPubMedCentral
28.
Lorvick J, Martinez A, Wenger L, Gee L, Kral A. Methamphetamine use among female injectors in San Francisco. Presented at the First National Conference on Methamphetamine, HIV and Hepatitis, Salt Lake City, UT. 2005.
29.
Roll JM. Contingency management: an evidence-based component of methamphetamine use disorder treatments. Addiction. 2007;102(Suppl. 1):114–20.CrossRefPubMed
30.
Winslow BT, Voorhees KI, Pehl KA. Methamphetamine abuse. Am Fam Physician. 2007;76(8):1167–74.
31.
California Department of Alcohol and Drug Programs, University of California LAISAP. Methamphetamine treatment: a practitioner’s reference 2007. Sacramento, CA: California Department of Alcohol and Drug Programs; 2007.
32.
Reback CJ, Larkins S, Shoptaw S. Changes in the meaning of sexual risk behaviors among gay and bisexual male methamphetamine abusers before and after drug treatment. AIDS Behav. 2004;8(1):87–98.CrossRefPubMed
33.
•• Roll JM, Chudzynski J, Cameron JM, Howell DN, McPherson S. Duration effects in contingency management treatment of methamphetamine disorders. Addict Behav. 2013;38(9):2445–62. This study supports the Contingency Management intervention and its effects over time on abstinence and reduced drug use among meth users.CrossRef
34.
•• Shoptaw S, Klausner JD, Reback CJ, et al. A public health response to the methamphetamine epidemic: the implementation of contingency management to treat methamphetamine dependence. BMC Public Health. 2006;6:214–8. This study supports the role of contingency management to treat meth dependence in myriad settings including non-traditional and traditional drug treatment programs.CrossRefPubMedPubMedCentral
35.
Menza TW, Jameson DR, Hughes JP, Colfax GN, Shoptaw S, Golden MR. Contingency management to reduce methamphetamine use and sexual risk among men who have sex with men: a randomized controlled trial. BMC Public Health. 2010;10:774.CrossRefPubMedPubMedCentral
36.
Brecht M-L, Greenwell L, Anglin MD. Methamphetamine treatment: trends and predictors of retention and completion in a large state treatment system (1992–2002). J Subst Abus Treat. 2005;29:295–306.CrossRef
37.
Skinner BF. The behavior of organisms: an experimental analysis. Englewood Cliffs, NJ: Prentice-Hall; 1938.
38.
Bigelow GE, Silverman K. Theoretical and empirical foundations of contingency management treatments for drug abuse. In: Higgins S, Silverman K, editors. Motivating behavior change among illicit-drug abusers: research on contingency management interventions. Washington, D.C.: American Psychological Association; 1999. p. 15–31.CrossRef
39.
Stitzer ML, Vandrey R. Contingency management: utility in the treatment of drug abuse disorders. Clin Pharmacol Ther. 2008;83(4):644–7.CrossRefPubMed
40.
41.
Stitzer M, Petry N. Contingency management for the treatment of substance abuse. Annu Rev Clin Psychol. 2006;2:411–34.CrossRefPubMed
42.
43.
Higgins ST, Heil SH, Lussier JP. Clinical implications of reinforcement as a determinant of substance use disorders. Annu Rev Psychol. 2004;55:431–61.CrossRefPubMed
44.
45.
Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction. 2006;101(2):192–203.CrossRefPubMed
46.
Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use: a meta-analysis. Addiction. 2006;101:1546–60.CrossRefPubMed
47.
Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F, Badger G. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry. 1993;150:763–9.CrossRefPubMed
48.
Higgins ST, Wong CJ, Badger GJ, Ogden DE, Dantona RL. Contingent reinforcement increases cocaine abstinence during outpatient treatment and 1 year of follow-up. J Consult Clin Psychol. 2000;68(1):64–72.CrossRefPubMed
49.
Stitzer ML, Walsh SL. Psychostimulant abuse: the case for combined behavioral and pharmacological treatments. Pharmacol Biochem Behav. 1997;57(3):457–70.CrossRefPubMed
50.
Petry NM. Contingency management in addiction treatment. Psychiatric Times. 2002;19(2).
51.
Rawson RA, McCann MJ, Flammino F, et al. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction. 2006;101:267–74.CrossRefPubMed
52.
53.
Higgins ST. Extending contingency management to the treatment of methamphetamine use disorders. Am J Psychiatry. 2006;163(11):1870–2.CrossRefPubMed
54.
Petry NM, Peirce JM, Stitzer ML, et al. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study. Arch Gen Psychiatry. 2005;62:1148–56.CrossRefPubMed
55.
Shoptaw S, Reback CJ. Methamphetamine use and infections disease-related behaviors in men who have sex with men: implications for interventions. Addiction. 2007;102(Suppl. 1):130–5.CrossRefPubMed
56.
Menza TW, Colfax G, Shoptaw S, et al. Interest in a methamphetamine intervention among men who have sex with men. Sex Transm Dis. 2007;34(4):209–14.CrossRefPubMed
57.
Rawson RA, Marinelli-Casey P, Anglin MD, et al. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction. 2004;99:708–17.CrossRefPubMed
58.
Silverman K, Higgins S, Brooner R, et al. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry. 1996;53:409–15.CrossRefPubMed
59.
Stitzer ML, Iguchi MY, Felch LJ. Contingent take-home incentive: effects on drug use of methadone maintenance patients. J Consult Clin Psychology. 1992;60:927–34.CrossRef
60.
Baker A, Lee NK. A review of psychosocial interventions for amphetamine use. Drug Alcohol Rev. 2003;22:323–35.CrossRefPubMed
61.
Petry NM, Alessi SM, Hanson T. Contingency management improves abstinence and quality of life in cocaine abusers. J Consult Clin Psychol. 2007;75(2):307–15.CrossRefPubMed
62.
Tracy K, Babuscio T, Nich C, Kiluk B, Carroll KM, Petry NM, et al. Contingency management to reduce substance use in individuals who are homeless with co-occurring psychiatric disorders. Am J Drug Alcohol Abuse. 2007;33:253–8.CrossRefPubMedPubMedCentral
63.
Weil M, Karls JM. Historical origins and recent developments. In: Weil M, Karls JM, editors. Case management in human service practice. San Francisco: Jossey-Bass, Inc.; 1989. p. 1–28.
64.
Mejta CL, Bokos PJ, Mickenberg J, Maslar ME, Senay E. Improving substance abuse treatment access and retention using a case management approach. J Drug Issues. 1997;27(2):329–40.CrossRef
65.
Siegal HA, Rapp RC, Kelliher CW, Fisher JH, Wagner JH, Cole PA. The strengths perspective of case management: a promising inpatient substance abuse treatment enhancement. J Psychoactive Drugs. 1995;27(1):67–72.CrossRefPubMed
66.
Hasson AL, Grella CE, Rawson R, Anglin MD. Case management within a methadone maintenance program: a research demonstration project for HIV risk reduction. J Case Manag. 1994;3:167–73.PubMed
67.
Shwartz M, Baker G, Mulvey KP, Plough A. Improving public policy funded substance abuse treatment: the value of case management. Am J Public Health. 1997;87(10):1659–64.CrossRefPubMedPubMedCentral
68.
Bokos P, Mejta C, Mickenberg J, Monks R. Case management: an alternative approach to working with intravenous drug users. In: Asher RS, editor. Progress and issues in case management. Rockville, MD: National Institute on Drug Abuse Monograph Series; 1992. p. 92–111.
69.
Siegal HA, Rapp RC, Li L, Saha P, Kirk KD. The role of case management in retaining clients in substance abuse treatment: an exploratory analysis. J Drug Issues. 1997;27:821–31.CrossRef
70.
Siegal HA, Fisher JH, Rapp RC, et al. Enhancing substance abuse treatment with case management: its impact on employment. J Subst Abus Treat. 1996;13:93–8.CrossRef
71.
Rapp RC, Otto AL, Lane DT, Redko C, McGatha C, Carlson RG. Improving linkage with substance abuse treatment using brief case management and motivational interviewing. Drug Alcohol Depend. 2008;94:172–82.CrossRefPubMedPubMedCentral
72.
Falck R, Carlson RG, Price SK, Turner JA. Case management to enhance HIV risk reduction among users of injection drugs and crack cocaine. J Case Manag. 1994;3:162–7.PubMed
73.
Mizuno Y, Purcell T, Borkowski K, Knight K. The life priorities of HIV-seropositive injection drug users: findings from a community-based sample. AIDS Behav. 2003;7:395–403.CrossRefPubMed
74.
Carlson RG, Siegal HA. The crack life: an ethnographic overview of crack use and sexual behaviors among African Americans in a Midwest metropolitan city. J Psychoactive Drugs. 1991;23:11–20.CrossRefPubMed
75.
Rapp RC, Siegal HA, Fisher JH. A strengths-based model of case management/advocacy: adapting a mental health model to practice work with persons who have substance abuse problems. NIDA Res Monogr. 1992;127:79–91.PubMed
76.
Rapp RC, Chamberlain R. Case management services for the chronically mentally ill. Soc Work. 1985;30:417–22.CrossRefPubMed
77.
Gardner LI, Metsch LR, Anderson-Mahoney P, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005;19(4):423–31.CrossRefPubMed
78.
•• Corsi KF, Booth RE. HIV sex risk behaviors among heterosexual methamphetamine users. Curr Drug Abuse Rev. 2008;1:292–6. This brief literature reviews shows the dearth of research on heterosexual meth users and HIV risk behaviors.CrossRefPubMed
79.
Sobell LC, Sobell MB. Timeline Followback user’s guide: a calendar method for assessing alcohol and drug use. Toronto: Addiction Research Foundation; 1996.
Metadata
Title
Interventions to Reduce Drug Use Among Methamphetamine Users at Risk for HIV
Authors
Karen F. Corsi
Steve Shoptaw
Musheng Alishahi
Robert E. Booth
Publication date
01-02-2019
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 1/2019
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-019-00423-y

Other articles of this Issue 1/2019

Current HIV/AIDS Reports 1/2019 Go to the issue

Behavioral Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Social Networks of Substance-Using Populations: Key Issues and Promising New Approaches for HIV

Behavioral Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Physiological Changes from Violence-Induced Stress and Trauma Enhance HIV Susceptibility Among Women

Central Nervous System and Cognition (SS Spudich, Section Editor)

HIV Eradication Strategies: Implications for the Central Nervous System

Behavioral Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Substance Use Screening in HIV Care Settings: a Review and Critique of the Literature

The Science of Prevention (JD Stekler and JM Baeten, Section Editors)

The Impact of ACA and Medicaid Expansion on Progress Toward UNAIDS 90-90-90 Goals

Behavioral Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

The Association Between Marijuana Use and HIV Continuum of Care Outcomes: a Systematic Review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits